PCM
APLS

Prelude Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Prelude Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200
Closed -$6K – 1415
2019
Q4 		$6K Buy
+200
New +$5.54K ﹤0.01% 1753

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's APLS Position: Q2 2026 in Review

Prelude Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 111,468 shares — an estimated $4.48M sold.

Prelude Capital Management first reported a position in APLS in Q4 2018 and held it in 14 quarters. The position peaked at $4.48M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Prelude Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 111,468 Apellis Pharmaceuticals shares in Q2 2026, an estimated $4.48M.
  • Prelude Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 14 quarters.
  • Prelude Capital Management's Apellis Pharmaceuticals position peaked at $4.48M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.